Nurix Therapeutics, Inc.
NRIX · United States
Share price · NRIX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when NRIX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Nov 2026-38.2%
- 14 Oct 2026+7.0%
- 25 Jun 2026+16.4%
Nothing announced by NRIX that day or the session before.
- 11 Jun 2026+11.0%
- 8 Jun 2026+6.8%
- 3 Jun 2026-5.4%
Nothing announced by NRIX that day or the session before.
- 21 May 2026+6.8%
Nothing announced by NRIX that day or the session before.
- 28 Apr 2026+3.6%
Nothing announced by NRIX that day or the session before.
- 8 Apr 2026-4.6%
- 8 Dec 2025+18.7%
Nothing announced by NRIX that day or the session before.
Share of unusual movement by asset
For each asset, the share of NRIX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Bruton's tyrosine kinase (BTK)Small molecule | Chronic Lymphocytic Leukemia Relapsed/Refractory Chronic Lymphocytic Leukemia | |
| Phase 1 | Cbl-bSmall molecule | Non-Small Cell Lung Cancer |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $673M | $79M | $720M+ $328M short-term inv. | —$616M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $88M | $68M+ $376M short-term inv. | $90M-$97M operating cash flow | report ↗ |
| 2026-Q1 | — | $84M | $71M+ $470M short-term inv. | $87M-$72M operating cash flow | report ↗ |
| 2025-Q3 | — | $86M | $78M+ $350M short-term inv. | $86M-$57M operating cash flow | report ↗ |
| 2025-Q2 | — | $78M | $84M+ $402M short-term inv. | $43M-$63M operating cash flow | report ↗ |
| 2025-Q1 | — | $70M | $76M+ $474M short-term inv. | $56M-$61M operating cash flow | report ↗ |
| 2024-Q3 | — | $55M | $99M+ $349M short-term inv. | $49M-$42M operating cash flow | report ↗ |
| 2024-Q2 | — | $49M | $117M+ $326M short-term inv. | $45M-$40M operating cash flow | report ↗ |
| 2024-Q1 | $17M | $50M | $50M+ $194M short-term inv. | $42M-$42M operating cash flow | report ↗ |
| 2023-Q3 | $18M | $48M | $42M+ $217M short-term inv. | $37M-$41M operating cash flow | report ↗ |
| 2023-Q2 | $31M | $46M | $59M+ $222M short-term inv. | $24M-$18M operating cash flow | report ↗ |
| 2023-Q1 | $13M | $46M | $34M+ $244M short-term inv. | $41M-$48M operating cash flow | report ↗ |
| 2022-Q3 | $11M | $48M | $48M+ $297M short-term inv. | $46M-$46M operating cash flow | report ↗ |
| 2022-Q2 | $11M | $47M | $42M+ $256M short-term inv. | $45M-$33M operating cash flow | report ↗ |
| 2022-Q1 | $9.6M | $43M | $79M+ $183M short-term inv. | $43M-$43M operating cash flow | report ↗ |
| 2021-Q3 | $10M | $31M | $147M+ $196M short-term inv. | $29M-$30M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $317M | $247M+ $346M short-term inv. | $66M-$249M operating cash flow | report ↗ |
For fiscal year 2025, Nurix Therapeutics did not disclose revenue. Research and development spend was $316.9M, up 43.0% YoY, and the company reported cash and equivalents of $246.96M with a net loss of $264.46M.
Nurix is a clinical-stage biopharmaceutical company advancing targeted protein degradation medicines. In October 2025, it initiated a potentially pivotal Phase 2 study of bexobrutideg in relapsed/refractory CLL, while continuing Phase 1a/1b studies for zelebrudomide and NX-1607. Partnered programs with Gilead, Sanofi, and Pfizer advanced, including FDA clearance of an IND for GS-6791/NX-0479 and Sanofi licensing NX-3911; collaborations have generated $482.0M in non-dilutive funding to date, with up to $6.1B in potential future fees and milestones.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $222M | $110M+ $500M short-term inv. | $48M-$173M operating cash flow | report ↗ |
| 2023-FY | $77M | $189M | $55M+ $233M short-term inv. | $36M-$81M operating cash flow | report ↗ |
| 2022-FY | $39M | $185M | $64M+ $245M short-term inv. | $45M-$160M operating cash flow | report ↗ |
| 2021-FY | $30M | $116M | $81M+ $215M short-term inv. | $29M-$84M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 48 sales ($5.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-04 | van Houte Hans · Chief Financial Officer | Open-market sale | 3,300 | $15.38 | $51K | Form 4 |
| 2026-11-04 | van Houte Hans · Chief Financial Officer | Open-market sale | 1,469 | $16.20 | $24K | Form 4 |
| 2026-11-03 | Ring Christine · Chief Legal Officer | Open-market sale | 6,113 | $25.83 | $158K | Form 4 |
| 2026-11-02 | Ring Christine · Chief Legal Officer | Option exercise | 5,786 | $8.72 | $50K | Form 4 |
| 2026-11-02 | Ring Christine · Chief Legal Officer | Open-market sale | 9,527 | $25.74 | $245K | Form 4 |
| 2026-11-02 | Ring Christine · Chief Legal Officer | Open-market sale | 1,075 | $26.76 | $29K | Form 4 |
| 2026-11-02 | Ring Christine · Chief Legal Officer | Option exercise (derivative) | 5,786 | — | — | Form 4 |
| 2026-11-02 | Hansen Gwenn · Chief Scientific Officer | Option exercise | 1,452 | $1.86 | $3K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 194 reporting institutions held 117.3M shares ($1.8B, 107.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 8,925,642 | $138.3M |
| 2 | Redmile Group, LLC | 7,732,808 | $119.9M |
| 3 | Vestal Point Capital, LP | 6,500,000 | $100.8M |
| 4 | Deep Track Capital, LP | 6,345,244 | $98.4M |
| 5 | FMR LLC | 5,541,271 | $85.9M |
| 6 | STATE STREET CORP | 5,141,195 | $79.7M |
| 7 | MORGAN STANLEY | 4,931,999 | $76.4M |
| 8 | BAKER BROS. ADVISORS LP | 4,658,556 | $72.2M |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 4,427,112 | $68.6M |
| 10 | GENERAL ATLANTIC, L.P. | 4,101,865 | $63.6M |
| 11 | PERCEPTIVE ADVISORS LLC | 3,710,877 | $57.5M |
| 12 | Pictet Asset Management Holding SA | 2,726,138 | $42.3M |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 2,520,229 | $39.1M |
| 14 | Rubric Capital Management LP | 2,473,885 | $38.3M |
| 15 | DEUTSCHE BANK AG\ | 2,295,024 | $35.6M |